Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Public Sector Pension Investment Board

Public Sector Pension Investment Board boosted its position in Moderna, Inc. (NASDAQ:MRNA) by 18.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,380 shares of the company’s stock after purchasing an additional 2,500 shares during the period. Public Sector Pension Investment Board’s holdings in Moderna were worth $1,095,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in MRNA. Simplicity Wealth LLC lifted its holdings in shares of Moderna by 31.6% in the 2nd quarter. Simplicity Wealth LLC now owns 4,838 shares of the company’s stock valued at $575,000 after buying an additional 1,161 shares during the period. Czech National Bank raised its position in Moderna by 8.9% in the second quarter. Czech National Bank now owns 63,536 shares of the company’s stock worth $7,545,000 after acquiring an additional 5,170 shares in the last quarter. Granite Bay Wealth Management LLC acquired a new stake in Moderna in the second quarter valued at $524,000. Sequoia Financial Advisors LLC boosted its position in shares of Moderna by 7.1% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 8,722 shares of the company’s stock worth $1,036,000 after purchasing an additional 575 shares in the last quarter. Finally, Wedmont Private Capital grew its stake in shares of Moderna by 48.4% during the 2nd quarter. Wedmont Private Capital now owns 3,075 shares of the company’s stock worth $373,000 after purchasing an additional 1,003 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO James M. Mock sold 715 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 7.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,850 shares of company stock valued at $134,560 over the last quarter. Company insiders own 15.70% of the company’s stock.

Moderna Stock Performance

Moderna stock opened at $44.44 on Friday. The stock has a fifty day moving average price of $50.27 and a 200 day moving average price of $87.86. Moderna, Inc. has a 52 week low of $35.80 and a 52 week high of $170.47. The firm has a market capitalization of $17.10 billion, a P/E ratio of -7.64 and a beta of 1.58. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the prior year, the company posted ($1.39) EPS. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. Equities research analysts anticipate that Moderna, Inc. will post -9.32 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on MRNA. Piper Sandler reiterated an “overweight” rating and issued a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Royal Bank of Canada reissued a “sector perform” rating and set a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. TD Cowen dropped their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research note on Friday, September 13th. Jefferies Financial Group decreased their target price on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research report on Tuesday, October 15th. Finally, HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research report on Monday, November 18th. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $83.33.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.